CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Anida Pharma, Inc. announced today that it has been awarded funding by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to conduct pre-clinical research using its lead compound for treatment of neurodegenerative diseases, Neuroprotectin D1 (NPD1). This is Anida Pharma’s first grant from MJFF.
“The grant will not only provide funding but, equally important, will bring Anida into the network of outstanding experts that support MJFF’s mission to accelerate translational research and bring new disease-modifying treatment options to patients with Parkinson’s disease. The collaboration marks a significant step for Anida, and we will be looking forward to building our scientific relationship with the Foundation,” said Per Gjorstrup, MD, PhD, President and CEO of Anida Pharma.
NPD1 is an endogenous DHA-derived lipid mediator that regulates circuits of resolution. It has a unique multi-modal effect profile with regulation of neuroinflammation, including activation of M2 microglia, without being immunosuppressive. NPD1 equally activates prosurvival pathways with stimulation of neurite outgrowth, and inhibits apoptosis by regulating protein phosphorylation, leading to reduced proteotoxic cell death. Preliminary preclinical studies in neurodegenerative disease show that NPD1 can be successfully delivered to the CNS.
“A drug that simultaneously acts on several pathways implicated in Parkinson’s disease pathophysiology has particular potential as a disease-modifying therapeutic,” said Sonal Das, PhD, senior associate director of research programs at MJFF. “The complexity of the human disease process suggests that a multi-modal approach such as that of NPD1 may increase the probability of clinical success.”
The Michael J. Fox Foundation for Parkinson's Research
As the world's largest private funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $350 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.
Anida Pharma, Inc.
Anida is a biopharmaceutical company developing novel first-in-class therapies to treat Parkinson’s disease, amyotrophic lateral sclerosis (ALS; Lou Gehrig disease), other central nervous system disorders, and hearing loss. Our therapeutic concept is based on activating the body’s own homeostatic mechanisms to regulate inflammation, prevent cell death and stimulate tissue repair. Visit our website: www.anidapharma.com to learn more.